Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Anxiety, Chills, Condition aggravated, Dizziness, Dyspnoea
Clinical narrative: feeling as though I am about to past out; Swollen armpit; Left Arm hurt and feels numb from spatula to phalanges; Left Arm hurt and feels numb from spatula to phalanges; Nauseous; jittery; dizziness; anxious; feeling short of breath; Pressure in my head; feeling hot and cold; chills; Drenched in sweat after waking up; Heart racing; fatigue; My anxiety has worsen.; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 36 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 22Feb2022 11:45 (Lot number: fk9729) at the age of 36 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing); "hyperactive thyroid" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: Covid-19 vaccine (Dose 1, Manufacturer unknown), for Covid-19 immunization; Covid-19 vaccine (Dose 2, Manufacturer unknown), for Covid-19 immunization. The following information was reported: LOSS OF CONSCIOUSNESS (medically significant) with onset 23Feb2022 03:00, outcome "not recovered", described as "feeling as though I am about to past out"; PERIPHERAL SWELLING (non-serious) with onset 23Feb2022 03:00, outcome "not recovered", described as "Swollen armpit"; PAIN IN EXTREMITY (non-serious), HYPOAESTHESIA (non-serious) all with onset 23Feb2022 03:00, outcome "not recovered" and all described as "Left Arm hurt and feels numb from spatula to phalanges"; NAUSEA (non-serious) with onset 23Feb2022 03:00, outcome "not recovered", described as "Nauseous"; FEELING JITTERY (non-serious) with onset 23Feb2022 03:00, outcome "not recovered", described as "jittery"; DIZZINESS (non-serious) with onset 23Feb2022 03:00, outcome "not recovered", described as "dizziness"; ANXIETY (non-serious) with onset 23Feb2022 03:00, outcome "not recovered", described as "anxious"; DYSPNOEA (non-serious) with onset 23Feb2022 03:00, outcome "not recovered", described as "feeling short of breath"; HEAD DISCOMFORT (non-serious) with onset 23Feb2022 03:00, outcome "not recovered", described as "Pressure in my head"; FEELING OF BODY TEMPERATURE CHANGE (non-serious) with onset 23Feb2022 03:00, outcome "not recovered", described as "feeling hot and cold"; CHILLS (non-serious) with onset 23Feb2022 03:00, outcome "not recovered", described as "chills"; HYPERHIDROSIS (non-serious) with onset 23Feb2022 03:00, outcome "not recovered", described as "Drenched in sweat after waking up"; PALPITATIONS (non-serious) with onset 23Feb2022 03:00, outcome "not recovered", described as "Heart racing"; FATIGUE (non-serious) with onset 23Feb2022 03:00, outcome "not recovered", described as "fatigue"; CONDITION AGGRAVATED (non-serious) with onset 23Feb2022 03:00, outcome "not recovered", described as "My anxiety has worsen.". Therapeutic measures were not taken as a result of loss of consciousness, peripheral swelling, pain in extremity, hypoaesthesia, nausea, feeling jittery, dizziness, anxiety, dyspnoea, head discomfort, feeling of body temperature change, chills, hyperhidrosis, palpitations, fatigue, condition aggravated.  Clinical Course: Patient mentioned that she did not experience this with the first or the second dose. This booster is crap. Patient did not receive any other vaccines within 4 weeks and other medications within 2 weeks to the COVID vaccine. The patient was not tested positive for covid 19 prior to vaccination and had not been tested post vaccination. Patient had no known allergies.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Based on the information available, the causal relationship between the reported events and suspect drug BNT162B2 cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate